Virtual Care: A New Era in Neurology

By Staff Writer

September 6, 2023

As the world grapples with an ageing population and increasing prevalence of chronic diseases, the demand for continuous home and institutional care is expected to rise significantly. This growing need, coupled with the ongoing COVID-19 pandemic, has led to a major advance in the use of virtual care tools. These tools have been instrumental in ensuring access to care and services, promoting continuity of care, and are now being integrated into care pathways for the evaluation, treatment, and follow-up of patients in specialty medicine, particularly neurology.

The Ministère de la Santé et des Services sociaux (MSSS) has initiated a national project on virtual care, mandating the Institut national d’excellence en santé et en services sociaux (INESSS) to provide a state-of-knowledge report to guide the use of virtual care in specialty medicine. This initiative aims to inform public decision-makers, medical associations, and health and social services professionals about virtual care practices in specialty medicine.

The project comprises seven reports, one of which focuses on neurology. The report presents a scoping review of the care pathways that can be supported or optimised with the use of virtual care. The review encompassed scientific and grey literature from the past five years, existing national and international guidelines, guidance and discussion papers, and health technology assessment (HTA) reports.

The findings from the review suggest that telerehabilitation is the most studied intervention across all care pathways. The review also highlights the need for additional good-quality studies to further validate the effectiveness of virtual care interventions.

The report also outlines several care pathways in neurology that have been reported as being clinically effective through the use of virtual care. These include identifying and diagnosing mild and major neurocognitive disorders via teleconsultation, improving cognitive functions through telerehabilitation via videoconferencing, and improving motor functions through physical telerehabilitation via videoconferencing among others.

Despite the promising results, the report also acknowledges the limitations of the study and the need for further research to clarify certain aspects of virtual care. Nevertheless, the findings provide valuable insights into the potential of virtual care in transforming the field of neurology and healthcare as a whole.

As the world continues to navigate through the challenges of the pandemic, the integration of virtual care in healthcare systems worldwide is more important than ever. It is hoped that with continued research and advancements in technology, virtual care will continue to improve access to healthcare and foster patient engagement in managing their illnesses. 

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.